46 results about "Film Dosage Form" patented technology

The present invention relates to products and methods of making products having a taste masked active component. In particular, the present invention relates to taste-masked film dosage forms including at least one active component and a slow dissolving basic composition.

Improved pharmaceutical solid oral film dosage forms for the buccal and / or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and / or sublingual absorption and / or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix.

The present invention relates to a method for forming a pharmaceutical product, such as a dissolvable film dosage form, onto a surface. Particularly, the present invention relates to a method of forming a pharmaceutical product directly onto the surface of a substrate.

An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Oral thin film dosage form of a stable dispersion of non-solubilized amorphous or partially amorphous active agent(s), having a mean particle size diameter D50 equal or less than 250 μm, that remains uniformly distributed within a film matrix and contains at least one film forming polymer, and optional pharmaceutically-acceptable excipients, such as diluents, plasticizers, surfactants, sweeteners, and taste-masking agent(s), are prepared by a process including first providing the active agent in an amorphous particle form having a mean particle size diameter D50 equal or less than 250 μm. Next, the active agent is suspended in a liquid film-forming formulation without dissolving the active agent. Therefore, the solvent is removed to form a film.

The present invention relates to products and methods of making products having a taste masked active component. In particular, the present invention relates to taste-masked film dosage forms including at least one active component and a slow dissolving basic composition.

The present invention relates to rapidly dissolving edible film dosage form incorporating a physical-chemical identifier and / or indicia. The physical-chemical identifier and / or indicia may correspond to an active ingredient that may be evenly distributed throughout the film. The physical-chemical identifier and / or indicia may be associated with at least one section of the film composition and / or associated with a sealed pouch or package containing the film composition and provide information to the consumer, practitioner, producer or regulator that is relevant to the edible film dosage form.

The invention relates to orally administrable, disintegrating film dosage forms which include ondansetron and methods of orally administering the film dosage forms.

An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Improved pharmaceutical solid oral film dosage forms for the buccal and / or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and / or sublingual absorption and / or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix.

Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.

An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

The present invention relates to a traditional Chinese medicine film spraying agent for promoting blood circulation, stopping bleeding, removing necrotic tissues and promoting tissue regeneration. Thetraditional Chinese medicine film spraying agent is prepared from the following components in 1,000 ml: Chinese rhubarb, coptis root, pseudo-ginseng, radix angelicae, donkey-hide gelatin, rhizoma bletillae, vinegar myrrh, radix rubiae, resina draconis, liquorice, pearl, borneol, a film forming material, a plasticizer, an aromatic, a preservative and 95% ethanol. Zhikang capsule is creatively improved into an external spraying film dosage form, during use, a spraying head of a spraying bottle is aimed at affected parts of traumatic injury for spraying, sprayed liquid medicine is quickly formedinto a film, so that effective components of the medicines are favorably soaked into the affected parts to generate a biochemical reaction, the medicines are not liable to lose, and a better treatment effect is generated; and the film spraying agent has obvious effects of promoting blood circulation, stopping bleeding, relieving swelling and pains, removing necrotic tissues, promoting tissue regeneration, inhibiting micro-organisms and diminishing inflammation, simultaneously is free of any hormone medicines, has advantages of high safety and low side effect, simultaneously sprays the liquidmedicine to form the film quickly, the effective components of the medicines are not liable to lose, and the better treatment effect is generated.

An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and / or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.

The present invention relates to a film preparation for oral administration, containing tadalafil free base, and a preparation method therefor. The invention provides a film. It is possible to: maximize the dispersion stability of tadalafil free base in the film by using a small amount of a dispersion stabilizer without inducing a specific odor or taste which can occur when using other dispersion stabilizers known in the relevant art; provide a film having an extremely low rate of tadalafil free base particle reaggregation; and remarkably reduce the amount of bubbles during a preparation process.